

# Self-management and congestive heart failure: a randomized controlled trial to improve health-behavior and health-related quality of life by increasing self-efficacy expectancies in congestive heart failure patients

<b>Submission date</b> 27/01/2006	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 27/01/2006	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 14/09/2017	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Esther STF Smeulders

**Contact details**  
University Maastricht  
Faculty of Health Sciences  
Department of Health Care Studies Section of Medical Sociology  
PO Box 616  
Maastricht  
Netherlands  
6200 MD  
+31 (0)43 3884183  
E.Smeulders@ZW.unimaas.nl

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**

NHS, number 2002B005; NTR467

## **Study information**

### **Scientific Title**

Self-management and congestive heart failure: a randomized controlled trial to improve health-behavior and health-related quality of life by increasing self-efficacy expectancies in congestive heart failure patients

### **Study objectives**

1. Self-efficacy expectancies may increase by the 'Chronic Disease Self-Management Program' in congestive heart failure intervention patients as compared to controls
2. These higher levels of self-efficacy expectancies contribute to health behavior, and will decrease demoralization (depressive symptoms, feelings of anxiety) and functional disability and increase levels of quality of life

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Not provided at time of registration

### **Study design**

Randomised controlled trial

### **Primary study design**

Interventional

### **Secondary study design**

Randomised controlled trial

### **Study setting(s)**

Not specified

### **Study type(s)**

Prevention

### **Participant information sheet**

### **Health condition(s) or problem(s) studied**

Congestive heart failure

### **Interventions**

1. Patients in the intervention group attend a protocolled self-management group course (6 weekly sessions of 2.5 hours per session)
2. Patients assigned to the control group received usual care

## **Intervention Type**

Other

## **Phase**

Not Specified

## **Primary outcome measure**

1. Self-efficacy expectancies:
  - a. General expectancies: General Self-Efficacy Scale (GSES)
  - b. Cardiac expectancies by scale Sullivan et al. (1998)
2. Perceived control/mastery by Mastery scale (Pearlin & Schooler 1978)

## **Secondary outcome measures**

1. Quality of life:
  - a. General: RAND/SF-36
  - b. CHF-specific: Kansas City Cardiomyopathy Questionnaire (KCCQ)
  - c. Symptoms of anxiety/depression: Hospital Anxiety & Depression Scale (HADS)
2. Health behavior:
  - a. Lifestyle
  - b. Physical activity level
  - c. Self-care behavior (European Heart Failure Self-Care Behavior Scale)
3. Health care utilization (number of consultations of cardiologist/nurse specialist, hospitalization days, etc.)

In addition, the following variables are assessed with respect to the process evaluation: performance according to protocol, attendance, overall adherence per course session /adherence with regard to home work assignments, opinions about the intervention (participants + course leaders), etc.

## **Overall study start date**

15/12/2003

## **Completion date**

15/12/2007

# **Eligibility**

## **Key inclusion criteria**

1. Extent of congestive heart failure (CHF): systolic CHF; LVEF <40% (NYHA 2-3) or diastolic CHF (NYHA 2-3 + additional hospital admission Decompensatio Cordis after being diagnosed with CHF)
2. Diagnosis of CHF at least 3 months ago to include only stable patients (an additional 3 months before the start of the intervention sums up to 6 months)
3. Ability to understand/write/speak Dutch

## **Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Both

**Target number of participants**

318

**Key exclusion criteria**

Participation in other scientific research

**Date of first enrolment**

15/12/2003

**Date of final enrolment**

15/12/2007

## **Locations**

**Countries of recruitment**

Netherlands

**Study participating centre**

**University Maastricht**

Maastricht

Netherlands

6200 MD

## **Sponsor information**

**Organisation**

CAPHRI, The Research Institute of the University Maastricht (The Netherlands)

**Sponsor details**

PO Box 616

Maastricht

Netherlands

6200 MD

+31 (0)43 3882446

e.habets@caphri.unimaas.nl

**Sponsor type**

Not defined

**ROR**

<https://ror.org/02jz4aj89>

## Funder(s)

**Funder type**

Research organisation

**Funder Name**

Netherlands Heart Foundation (Nederlandse Hartstichting), University Hospital Maastricht

## Results and Publications

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Protocol article</a>	protocol	20/07/2006		Yes	No
<a href="#">Results article</a>	results	01/11/2010		Yes	No